Literatur
Specks U, Merkel PA, Seo P et al (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369:417–427
Smith RM, Jones RB, Guerry MJ et al (2012) Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3760–3769
Cartin-Ceba R, Golbin JM, Keogh KA et al (2012) Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum 64(11):3770–3778
Pendergraft WF III, Cortazar FB, Wenger J et al (2014) Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol 9(4):736–744
Hiemstra TF, Walsh M, Mahr A et al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304(21):2381–2388
Interessenkonflikt
B. Hellmich gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hellmich, B. Remissionserhaltung mit Methotrexat, Azathioprin oder Mycophenolat-Mofetil nach Induktionstherapie mit Rituximab bei Granulomatose mit Polyangiitis. Z. Rheumatol. 74, 157–158 (2015). https://doi.org/10.1007/s00393-014-1520-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-014-1520-y